|drug837||The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki||0.45|
|drug842||Thiazide or Thiazide-like diuretics Wiki||0.45|
|drug50||Angiotensin receptor blocker Wiki||0.45|
|drug223||Control swab Wiki||0.45|
|drug947||convalescent plasma from recovered COVID 19 donor Wiki||0.45|
|drug659||Prototype swab Wiki||0.45|
|drug167||Calcium Channel Blockers Wiki||0.45|
|drug21||ACE inhibitor Wiki||0.32|
|D014552||Urinary Tract Infections NIH||0.45|
|D000309||Adrenal Insufficiency NIH||0.45|
|D001997||Bronchopulmonary Dysplasia NIH||0.45|
|D002318||Cardiovascular Diseases NIH||0.13|
|D003141||Communicable Diseases NIH||0.05|
|D018352||Coronavirus Infections NIH||0.05|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
There are 5 clinical trials
There are currently no clinical studies reporting clinical characteristics difference between the hypertension patients with and without ACEI treatment when suffered with novel coronavirus infection in China.
Description: The percentage of patients admitted to the ICU at any time during the 28 days of onset COVID-19.Measure: Occupancy rate in the intensive care unit (ICU) Time: up to 28 days
Description: The number of patients requiring mechanical ventilation.Measure: Mechanical Ventilation Time: up to 28 days
Description: The number of patients who died of 2019-nCoV infection.Measure: Death Time: up to 28 days
Description: The number of died 2019-nCoV infected patients from any cause.Measure: All cause mortality Time: up to 28 days
Description: Time from onset of symptoms to admitted to the ICU, requiring mechanical ventilation, and death.Measure: Time from onset of symptoms to main outcome and its components Time: up to 28 days
Description: Time to Clinical RecoveryMeasure: Time to Clinical Recovery Time: up to 28 days
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACEI / ARB is the main target of antihypertensive drugs. Previous reports suggested that there were large number of patients with covid19 also suffered from hypertension, suggesting that patients with hypertension may be the susceptible to covid19. Therefore, we try to follow up the patients admitted to Hankou hospital to explore the impact of hypertension and hypertension treatment on the severity and prognosis of patients with covid19, so as to provide new methods for the treatment of patients with covid19 in the future.
Description: mortality in 28-dayMeasure: Rate of Death Time: From date of admission until the date of death from any cause, up to 60 days
Description: evaluate the severity of pneumonia according to CT scans and clinical manifestationMeasure: the severity of pneumonia Time: From date of admission until the date of discharge or death from any cause, up to 60 days
Description: days from admission to discharge or deathMeasure: the length of hospital stay Time: From date of admission until the date of discharge or death from any cause, up to 60 days
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is known to require the angiotensin-converting enzyme 2 (ACE-2) receptor for uptake into the human body, there have been questions about whether medications that upregulate ACE-2 receptors might increase the risk of infection and subsequent complications. One such group of medications are anti-hypertensives that block the renin-angiotensin system, including both angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB). Both ACEi and ARB are widely used for the treatment of hypertension. Early reports from China and Italy suggest that many of those who die from COVID-19 have a coexisting history of hypertension. Consequently, there have been questions raised as to whether these 2 types of blood pressure medication might increase the risk of death among patients with COVID-19. However, it is well known that the prevalence of hypertension increases linearly with age. Therefore, it is possible that the high prevalence of hypertension and ACEi/ARB use among persons who die from COVID-19 is simply confounded by age (older people are at risk of both a history of hypertension and dying from COVID-19). Whether these commonly prescribed blood pressure medications increase the risk of COVID-19 or not remains unanswered. Statements from professional cardiology societies on both sides of the Atlantic have called for urgent research into this question. Our study aims to randomize patients with primary (essential) hypertension who are already taking ACEi/ARB to either switch to an alternative BP medication or continue with the ACEi/ARB that they have already been prescribed. Adults with compelling indications for ACEi/ARB will not be enrolled.
Description: Time from randomization to the first occurrence of any of the clinical events aboveMeasure: Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of Covid-19 positive participants who die Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of Covid-19 positive participants who require intubation in intensive care unit (ICU) Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV) Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: Number of SARS-CoV-2 positive participants Time: 12 months
Description: Performed in a random sub-sample of the cohort (both study arms)Measure: 24 hour mean systolic BP (mmHg) on ambulatory BP monitoring Time: 12 months
Description: Time from randomization to the first occurrence of aboveMeasure: All-cause mortality Time: 12 months
Multicentric non-profit observational study, in patients with COVID-19 hospitalized in Italy, conducted through a pseudonymised survey.
Description: Using anamnestic data collected from the health record of the hospital or of the general practitioner, we will count the number of COVID-19 patients enrolled that were treated with ACE Inhibitors or ARB.Measure: Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 months
Description: This study want to observe whether the assumption of antihypertensive ACE inhibitors or ARB increases the severity of the clinical manifestation of COVID19Measure: Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents Time: 3 months
Description: Collecting selected data from the health record and hospital charts of the patients we will assess whether among the recorded parameters there are any that can predict COVID19 prevalence and severityMeasure: Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity Time: 3 months